(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
UN panel says Israel operating 'de facto policy of torture' - 2How to watch the last supermoon of the year
- 3Step by step instructions to Analyze Senior Insurance Contracts Really.
- 4Single women risk rape and exploitation in search for better life in Europe
- 5Impact of NIH funding reductions felt in cancer and infectious disease trials
- My prescription costs what?! Pharmacists offer tips that could reduce your out-of-pocket drug costs
- Find the Captivating Professional flowerbeds of the US
- Hamas demanded displaced Gazans pay rent on beach tents amid torrential downpour, IDF reveals
- Savvy Tips for Seniors Hyundai IONIQ EV
- The most effective method to Guarantee Scholastic Honesty in Web-based Degrees
- 25 of the world’s best sandwiches
- Finding the Universe of Computer generated Reality: Individual Encounters
- Opening Potential: Self-awareness and Long lasting Learning
- Data centers in space: Will 2027 really be the year AI goes to orbit?
